Other preclinical studies have shown that treatment with platinum drugs and cetuximab in combination with gefitinib in colon and lung cancer cells resulted in antagonistic effects because of inhibition of chemotherapy-induced ROS by EGFR-targeted agents (27,31). This evidence concerns the gene EGFR and lung cancer.